Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Mana.bio
Mana.bio is a seed stage biotech company leveraging AI, machine learning, and nanotechnology to design novel lipid nanoparticle (LNP) drug delivery systems for targeted extrahepatic delivery of…
Mana.bio
Mana.bio is a seed stage biotech company leveraging AI, machine learning, and nanotechnology to design novel lipid nanoparticle (LNP) drug delivery systems for targeted extrahepatic delivery of…
TL;DR
Stage: Seed
Core focus: AI-driven design of lipid nanoparticles for extrahepatic delivery of nucleic acid therapeutics
Recent disclosed seed raise: $19.5M (announced Oct 2023)
Founders / leadership: Yogev Debbi (CEO), Roy Nevo (CTO)
Company Overview
Problem Domain
Drug delivery for nucleic-acid therapeutics (mRNA, DNA, oligonucleotides) and gene therapies; extrahepatic targeting of LNPs.
Founded
2021
Industry
Biotechnology
Funding Track Record
$19.5M
Round described as oversubscribed with participation from Base4 Capital, NFX, LionBird, and Technion
Investor Signal
“Participation from prominent biotech investor Andreessen Horowitz Bio + Health and other institutional investors”